DURHAM, N.C. and FARMINGDALE, N.Y., July 29, 2021 -- Bioventus Inc. (BVS), a global leader in innovations for active healing, and Misonix, Inc. (MSON), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus (BVS) will acquire Misonix (MSON) in a cash-and-stock tran...
SOUTH PLAINFIELD, N.J., July 29, 2021 PTC Therapeutics, Inc. (PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2021.
LAS VEGAS, July 29, 2021 DelveInsight's Crohn's Disease Market report offers comprehensive coverage of the current treatment practices, pipeline drugs, Crohn's Disease market share of the individual therapies, current and forecasted Crohn's Disease market size from 2018 to 2030 segmented into 7MM (the USA, EU5, and Japan).
VANCOUVER, BC, July 29, 2021 -- The global biologics market size is expected to reach USD 477.15 billion in 2027 at a CAGR of 7.3% during the forecast period, according to the latest report by Emergen Research. Biologics are products produced from living organisms such as humans, animals, or microorganisms or certain components through biotechnology techniques.
ATLANTA, July 29, 2021 CryoLife (CRY), Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. (BAX), for up to $60.8 million in cash.
Sanofi raised its 2021 profit forecast on Thursday after its vaccines and star eczema treatment Dupixent helped it beat second-quarter results expectations. The French drugmaker said it was now targeting earnings per share growth of around 12% at constant exchange rates this year, up from "high single digit" percentage growth previously.
Regulatory News: Ipsen, a global specialty-driven biopharmaceutical company, today announced its financial results for the first half of 2021: David Loew, Chief Executive Officer, commented: “Our strong results reflected the progress we are making with our new strategy. Our raised expectations for our full-year results reflect the strength of our business.
Barry Deutsch is stepping down as CFO; remains key employee through the anticipated closing of previously announced transaction Steve Pieper, VP of Finance, assumes the role of CFO Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced executive ...
LAS VEGAS, July 28, 2021 DelveInsight's "Tendinopathy Market" report provides a thorough comprehension of the Tendinopathy historical and forecasted epidemiology and the Tendinopathy market trends in the 7MM [the United States, EU5 and Japan]. The Tendinopathy market report also proffers an analysis of the current Tendinopathy treatment algorithm/practice, market drivers, market barriers, and u...
FORT COLLINS, Colo. Shares of the new Cytocom's common stock will begin trading on Nasdaq under the ticker symbol "CBLI," at the opening bell on Wednesday, July 28, 2021. As previously reported, the newly combined company will operate as "Cytocom, Inc." under the leadership of the existing Cytocom management team led by CEO Michael K. Handley.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
